Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11133528 | 0.98 | SLC6A2 (0.54) | TAAR1SLC6A2MAOAAOC3MAOB | |
| SCHEMBL3802516 | 0.94 | MAOA (0.54) | TAAR1SLC6A2MAOAAOC3MAOB | |
| Hydrochloric Acid SCHEMBL17261340 | 0.92 | MAOB (0.53) | TAAR1SLC6A2MAOAAOC3MAOB | |
| SCHEMBL451516 | 0.86 | TAAR1 (0.60) | TAAR1SLC6A2MAOAAOC3MAOB | |
| Hydrochloric Acid SCHEMBL11164072 | 0.84 | TAAR1 (0.58) | TAAR1SLC6A2MAOAAOC3MAOB | |
| Water SCHEMBL2959270 | 0.84 | TAAR1 (0.58) | TAAR1SLC6A2MAOAAOC3MAOB | |
| Bromide SCHEMBL11038152 | 0.84 | TAAR1 (0.58) | TAAR1SLC6A2MAOAAOC3MAOB | |
| SCHEMBL6685035 | 0.82 | L3MBTL1 (0.48) | SLC6A2MAOAAOC3MAOBHTR2A | |
| SCHEMBL3132011 | 0.81 | CYP1A2 (0.50) | TAAR1IDO1CYP2A6SMN1; SMN2 | |
| SCHEMBL20343995 | 0.80 | SLC6A2 (0.44) | TAAR1SLC6A2MAOAAOC3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200076-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-02-09 | — | — | EP | claimed |
| EP-1200076-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2002-05-02 | — | — | EP | claimed |
| WO-2001008673-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-08 | — | — | WO | claimed |
| US-20220016613-A1 | NOVEL ANNULATION CATALYSTS VIA DIRECT C-H BOND AMINATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-01-20 | — | — | US | disclosed |
| EP-3212614-B1 | PROCESS FOR MAKING BENZOXAZINES | CYTEC IND INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-8039514-B2 | Sulfonamide compounds and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-8039514-B2 | Sulfonamide compounds and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-2292592-A1 | SULFONAMIDE COMPOUND AND APPLICATION THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-7902394-B2 | Calcilytic compounds | GLAXOSMITHKLINE LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100029782-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2120898-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008077009-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1200076-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1200076-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001008673-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-08 | — | — | WO | disclosed |
| US-4395410-A | Quaternary ammonium antiarrhythmic drugs | ELI LILLY AND COMPANY (US) | 1983-07-26 | — | — | US | disclosed |
| EP-0002604-B1 | QUATERNARY AMMONIUM SALTS, AND THEIR FORMULATIONS AND PREPARATION | ELI LILLY AND COMPANY (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4289787-A | PROLONG ACTION POTENTIAL OF CARDIAC TISSUE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0002604-A1 | Quaternary ammonium salts, and their formulations and preparation | ELI LILLY AND COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029782-A1 | Calcilytic Compounds | CALCR, CALCA, CALCB | TAAR1 3806/4885SLC6A2 1886/4885MAOA 3350/4885 |
| US-20220016613-A1 | NOVEL ANNULATION CATALYSTS VIA DIRECT C-H BOND AMINATION | AADAC, CAD, AOC1 | TAAR1 1815/4885SLC6A2 3657/4885MAOA 305/4885 |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | PTH1R, CASR, SOST | TAAR1 786/4885SLC6A2 3750/4885MAOA 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.